Results 101 to 110 of about 80,492 (287)

Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: Marker candidates for dementia with Lewy bodies [PDF]

, 2007
Background: The measurement of biomarkers in cerebrospinal fluid (CSF) has gained increasing acceptance in establishing the diagnosis of some neurodegenerative diseases.
Andreasen N, Brit Mollenhauer, Claudia Trenkwalder, Erik Bahn, Fahn S, Goetz CG, Hans A. Kretzschmar, Hoehn MM, Hughes AJ, Hulstaert F, Jens Wiltfang, Joseph J. Locascio, Knopman DS, Markus Otto, McKeith IG, McKhann G, Metz CE, Michael G. Schlossmacher, Mirko Bibl, Mollenhauer B, Oide T, Peter Brechlin, Petra Steinacker, Schlossmacher MG, Sigrid Poser, Takeuchi Y, Wiltfang J, Wodzig KW   +27 more
core   +1 more source

Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Deep brain stimulation (DBS) is effective for Parkinson's disease (PD); however, its efficacy varies with genetic background, such as the GBA1 variant—the causative gene of Gaucher disease—associated with increased PD risk and cognitive decline after subthalamic nucleus (STN)‐DBS.
Hikaru Kamo, Genko Oyama, Mai Shimizu, Haruka Takeshige‐Amano, Takashi Ogawa, Wataru Sako, Noriko Nishikawa, Taku Hatano, Yuanzhe Li, Hiroyo Yoshino, Manabu Funayama, Masanobu Ito, Hirokazu Iwamuro, Atsushi Umemura, Nobutaka Hattori   +14 more
wiley   +1 more source

Management of rapid eye movement sleep behavior disorder in patients with Parkinson's disease [PDF]

, 2016
Among all of the devastating effects that Parkinson’s disease (PD) has on an individual, sleep dysfunction is one that can have a profound effect on the entire family of the patient. The most potentially destructive of these sleep syndromes being that of
Jeffries, Michael
core   +1 more source

Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model. [PDF]

, 2019
Extensive loss of dopaminergic neurons, and aggregation of the protein α-synuclein into ubiquitin-positive Lewy bodies represents a major neuropathological hallmark of Parkinson's disease. At present the generation of large nuclear-associated Lewy bodies
Dalton, Caroline F, Duce, James A, Le Maitre, Christine L, Smith, David P, Taylor-Whiteley, Teresa R   +4 more
core   +2 more sources

Basal Forebrain Volume and Concurrent Hallucinations and Mild Cognitive Impairment in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Visual hallucinations (VH) and mild cognitive impairment (MCI) often co‐occur in Parkinson's Disease (PD). Each symptom in isolation is associated with cholinergic basal forebrain (BF) atrophy. However, it is unclear whether BF integrity relates to one symptom preferentially or to their co‐occurrence, and whether this relationship ...
Sabrina M. Adamo, Vaishali Mutreja, Marta Statucka, Batu Kaya, Taylor W. Schmitz, Anthony C. Ruocco, Melanie Cohn   +6 more
wiley   +1 more source

Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

Movement Disorders Clinical Practice, EarlyView.
Abstract Background α‐synuclein seeding amplification assay (α‐synuclein SAA) development as a diagnostic biomarker for Parkinson's disease (PD) has shown promising results over the past decade. However, the utility of these assays in the prediction of disease progression is unclear.
Daniel Belete, Christian Mattjie, Brook Huxford, Jonathan P. Bestwick, Alastair J. Noyce, Cristina Simonet   +5 more
wiley   +1 more source

Parkinson's Disease

MedEdPORTAL, 2012
Parkinson's disease is a degenerative disorder of the central nervous system resulting from the death of dopamine producing cells in the substantia nigra.
Douglas Gould, Lisa Haubert
doaj   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Lewy and his inclusion bodies: Discovery and rejection

Dementia & Neuropsychologia
Fritz Jacob Heinrich Lewy described the pathology of Paralysis agitans [Parkinson disease] and was the first to identify eosinophilic inclusion bodies in neurons of certain brain nuclei, later known as Lewy bodies, the pathological signature of the Lewy ...
Eliasz Engelhardt, Marleide da Mota Gomes   +1 more
doaj   +1 more source

Relation of neuropathology with cognitive decline among older persons without dementia

Frontiers in Aging Neuroscience, 2013
Objective: Although it is now widely accepted that dementia has a long preclinical phase during which neuropathology accumulates and cognition declines, little is known about the relation of neuropathology with the longitudinal rate of change in ...
Patricia eBoyle, Lei eYu, Robert eWilson, Julie eSchneider, David Alan Bennett   +4 more
doaj   +1 more source